These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 32918755)

  • 1. Efficacy of tocilizumab in COVID-19: A systematic review and meta-analysis.
    Aziz M; Haghbin H; Abu Sitta E; Nawras Y; Fatima R; Sharma S; Lee-Smith W; Duggan J; Kammeyer JA; Hanrahan J; Assaly R
    J Med Virol; 2021 Mar; 93(3):1620-1630. PubMed ID: 32918755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tocilizumab in addition to standard of care in the management of COVID-19: a meta-analysis of RCTs.
    Mutua V; Henry BM; Csefalvay CV; Cheruiyot I; Vikse J; Lippi G; Bundi B; Mong'are N
    Acta Biomed; 2022 Mar; 93(1):e2022014. PubMed ID: 35315395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tocilizumab in Hospitalized Patients with COVID-19: A Meta Analysis of Randomized Controlled Trials.
    Selvaraj V; Khan MS; Bavishi C; Dapaah-Afriyie K; Finn A; Lal A; Mylonakis E
    Lung; 2021 Jun; 199(3):239-248. PubMed ID: 34050796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis, first update.
    Tleyjeh IM; Kashour Z; Riaz M; Hassett L; Veiga VC; Kashour T
    Clin Microbiol Infect; 2021 Aug; 27(8):1076-1082. PubMed ID: 33915284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The COVIRL002 Trial-Tocilizumab for management of severe, non-critical COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial.
    Cotter A; Wallace D; McCarthy C; Feeney E; O'Neill L; Stack J; McCarthy G; Hussain R; Alvarez Barco E; Doran P; Mallon P
    Trials; 2020 Sep; 21(1):758. PubMed ID: 32883328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of tocilizumab on COVID-19 patient mortality: A systematic review and meta-analysis of randomized controlled trials.
    Lin WT; Hung SH; Lai CC; Wang CY; Chen CH
    Int Immunopharmacol; 2021 Jul; 96():107602. PubMed ID: 33812260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic Review and Meta-Analysis of Tocilizumab Therapy versus Standard of Care in over 15,000 COVID-19 Pneumonia Patients during the First Eight Months of the Pandemic.
    Mahroum N; Watad A; Bridgewood C; Mansour M; Nasr A; Hussein A; Khamisy-Farah R; Farah R; Gendelman O; Lidar M; Shoenfeld Y; Amital H; Kong JD; Wu J; Bragazzi NL; McGonagle D
    Int J Environ Res Public Health; 2021 Aug; 18(17):. PubMed ID: 34501738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of tocilizumab on mortality in hospitalized patients with COVID-19: a meta-analysis of randomized controlled trials.
    Kow CS; Hasan SS
    Eur J Clin Pharmacol; 2021 Aug; 77(8):1089-1094. PubMed ID: 33532896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tocilizumab in COVID-19: a meta-analysis, trial sequential analysis, and meta-regression of randomized-controlled trials.
    Snow TAC; Saleem N; Ambler G; Nastouli E; Singer M; Arulkumaran N
    Intensive Care Med; 2021 Jun; 47(6):641-652. PubMed ID: 34019122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beneficial and harmful outcomes of tocilizumab in severe COVID-19: A systematic review and meta-analysis.
    Rubio-Rivas M; Forero CG; Mora-Luján JM; Montero A; Formiga F; Homs NA; Albà-Albalate J; Sánchez L; Rello J; Corbella X
    Pharmacotherapy; 2021 Nov; 41(11):884-906. PubMed ID: 34558742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical efficacy and safety of interleukin-6 receptor antagonists (tocilizumab and sarilumab) in patients with COVID-19: a systematic review and meta-analysis.
    Yu SY; Koh DH; Choi M; Ryoo S; Huh K; Yeom JS; Yoon YK
    Emerg Microbes Infect; 2022 Dec; 11(1):1154-1165. PubMed ID: 35343397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
    Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
    Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tocilizumab in patients hospitalized with COVID-19 pneumonia: systematic review and meta-analysis of randomized controlled trials.
    Gupta S; Padappayil RP; Bansal A; Daouk S; Brown B
    J Investig Med; 2022 Jan; 70(1):55-60. PubMed ID: 34561232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tocilizumab treatment for COVID-19 patients: a systematic review and meta-analysis.
    Wei Q; Lin H; Wei RG; Chen N; He F; Zou DH; Wei JR
    Infect Dis Poverty; 2021 May; 10(1):71. PubMed ID: 34001244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.
    Salvarani C; Dolci G; Massari M; Merlo DF; Cavuto S; Savoldi L; Bruzzi P; Boni F; Braglia L; Turrà C; Ballerini PF; Sciascia R; Zammarchi L; Para O; Scotton PG; Inojosa WO; Ravagnani V; Salerno ND; Sainaghi PP; Brignone A; Codeluppi M; Teopompi E; Milesi M; Bertomoro P; Claudio N; Salio M; Falcone M; Cenderello G; Donghi L; Del Bono V; Colombelli PL; Angheben A; Passaro A; Secondo G; Pascale R; Piazza I; Facciolongo N; Costantini M;
    JAMA Intern Med; 2021 Jan; 181(1):24-31. PubMed ID: 33080005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased mortality and increased side effects in COVID-19 patients treated with IL-6 receptor antagonists: systematic review and meta-analysis.
    Malgie J; Schoones JW; Zeegers MP; Pijls BG
    Sci Rep; 2021 Nov; 11(1):21522. PubMed ID: 34728658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.
    Rilinger J; Kern WV; Duerschmied D; Supady A; Bode C; Staudacher DL; Wengenmayer T
    Trials; 2020 Jun; 21(1):470. PubMed ID: 32493514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal use of tocilizumab for severe and critical COVID-19: a systematic review and meta-analysis.
    Nugroho CW; Suryantoro SD; Yuliasih Y; Rosyid AN; Asmarawati TP; Andrianto L; Setiawan HW; Mahdi BA; Windradi C; Agustin ED; Fajar JK
    F1000Res; 2021; 10():73. PubMed ID: 33763201
    [No Abstract]   [Full Text] [Related]  

  • 19. Effectiveness of tocilizumab in non-intubated cases with COVID-19: a systematic review and meta-analysis.
    Keske Ş; Akyol M; Tanrıöver C; Özlüşen B; Akcan RE; Güler U; Sait B; Kaçmaz B; Gönen M; Ergönül Ö
    Infection; 2023 Dec; 51(6):1619-1628. PubMed ID: 37162716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tocilizumab administration for the treatment of hospitalized patients with COVID-19: A systematic review and meta-analysis.
    Kyriakopoulos C; Ntritsos G; Gogali A; Milionis H; Evangelou E; Kostikas K
    Respirology; 2021 Nov; 26(11):1027-1040. PubMed ID: 34605114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.